Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study

BACKGROUND: The EINSTEIN-Jr program will evaluate rivaroxaban for the treatment of venous thromboembolism (VTE) in children, targeting exposures similar to the 20 mg once-daily dose for adults. A physiologically based pharmacokinetic (PBPK) model for pediatric rivaroxaban dosing has been constructed...

Descripción completa

Detalles Bibliográficos
Autores principales: Willmann, Stefan, Thelen, Kirstin, Kubitza, Dagmar, Lensing, Anthonie W. A., Frede, Matthias, Coboeken, Katrin, Stampfuss, Jan, Burghaus, Rolf, Mück, Wolfgang, Lippert, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278136/
https://www.ncbi.nlm.nih.gov/pubmed/30534008
http://dx.doi.org/10.1186/s12959-018-0185-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6278136/
https://www.ncbi.nlm.nih.gov/pubmed/30534008
http://dx.doi.org/10.1186/s12959-018-0185-1

Ejemplares similares